Pfizer CentreOne vs Wacker Biotech: CDMO Comparison
How does Pfizer CentreOne compare to Wacker Biotech for mRNA/LNP manufacturing?
Side-by-side comparison of Pfizer CentreOne and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pfizer CentreOne has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Pfizer CentreOne maintains 3 MHRA / UK GMP certificates; Wacker Biotech does not.
- Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (368 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Pfizer CentreOne and Wacker Biotech qualify as mRNA/LNP manufacturers; Pfizer CentreOne carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Pfizer CentreOne and Wacker Biotech qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Pfizer CentreOne vs Wacker Biotech
How does Pfizer CentreOne compare to Wacker Biotech for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Pfizer CentreOne is 92/100 and Wacker Biotech is 82/100; Pfizer CentreOne has 4 FDA inspections on record vs 0 for Wacker Biotech; European coverage is 17 active EMA+MHRA certificates for Pfizer CentreOne vs 13 for Wacker Biotech. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Pfizer CentreOne or Wacker Biotech?
Both Pfizer CentreOne and Wacker Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Pfizer CentreOne has 4 FDA inspections on record; Wacker Biotech has 0.
How do Pfizer CentreOne and Wacker Biotech compare on European GMP coverage?
Pfizer CentreOne holds 14 active EMA GMP certificates and 3 MHRA / UK certificates. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Pfizer CentreOne or Wacker Biotech?
Pfizer CentreOne is matched to 368 ClinicalTrials.gov records as a manufacturing partner; Wacker Biotech is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — Pfizer CentreOne or Wacker Biotech?
Both Pfizer CentreOne and Wacker Biotech are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →